You will find global health economics scattered throughout my webpages, especially for infectious diseases (such as several published papers on the economics of dengue interventions) and as part of my graduate teaching. Here I gather cross-cutting economics writing and work that specifically analyses, so called, ‘innovative’ global health finance.

In 2016 I organised and edited a volume on the “Economics of Global Health”, Oxford Review of Economic Policy, OUP, Volume 32, Issue 1, SPRING 2016

This is my  introductory assessment: Farlow, A. (2016). The economics of global health: an assessment. Oxford Review of Economic Policy 32(1), 1-20.

The genus of this was a conference I organised  in September 2007, the Oxford Conference on Innovation and Technology Transfer for Global Health, from which I prepared the following Global Health Research Agenda. Reports from that conference  have been given a section below.

I am working on a paper on pandemic finance.  Till then, I am quoted here, here, here, here, here, and here. 

Some other papers that illustrate my thinking over time:

Farlow, A. (2011). Fixing GAVI’s cash crunch,  Human Vaccines and Immunotherapeutics, Vo 7, Issue 3 ,295-296,Landes Bioscience, 7(3),

Farlow, A. (2007).  A Global Medical Research and Development Treaty:  An answer to global health needs? International Policy Network Working Papers on Intellectual Property, Innovation and Health.

I contributed thoughts for a piece by Tatum Anderson in the British Medical Journal on  Innovative Financing of Health Care.

Farlow, A. (2009). Evaluation framework, evaluation criteria and Inventory of financing proposals for the WHO Expert Working Group on R&D Financing.Testimony for the WHO Expert Working Group on R&D Financing.

‘“Where’s all the money gone?” Financial crisis and global health spending: Priority setting past, present and future’, Vice Chancellor’s Global Health Research Forum, University of Oxford. September 2009

“Financial Meltdown and Neglected Diseases: Who will pay the price?” Talk given at launch event of first G-FINDER (Global Funding of Innovation for Neglected Diseases) report, Royal College of Physicians, London, February 2009. See the video of all speakers and panel and audience discussion here. Copy of talk here

Magnesium Sulfate for the Management of Eclampsia and Pre-eclampsia: Some Economic and Cost Reflections, PowerPoint presented in 2007, posted December 2008 following request

Farlow, A. (2005). Capital Costs, Cost-Effectiveness of HIV APC, and Speed of Vaccine Development WHO Commission on Intellectual Property Rights, Innovation and Public Health.

Costs of Monopoly Pricing under Patent Protection “Access to Medicines and the Financing of Innovations in Health Care” conference, The Program on Science, Technology, and Global Development at The Earth Institute at Columbia University, New York, December 2003

Tobin Tax: Alternative Finance for Health R&D? Presentation for the Rockefeller Foundation Bellagio Frati Dialogue, Bellagio, Italy, September 24-29, 2003. Contains an evaluation of the Tobin Tax as a mechanism to raise finance for health R&D

The cost of R&D: How much money is needed to address the current need? PowerPoint presentation at Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines, International Conference on Ensuring Innovation for Neglected Diseases, London, United Kingdom, 8 June 2005

Purchase Commitments for Vaccines: Their Uses and Their Limitations PowerPoint presentation at the Biodesign Institute, Arizona State University, 5 April 2005, updated 16 May 2005.

Farlow, A., Light, D. Mahoney, R., and Widdus, R. (2005). Concerns Regarding “Making Markets for Vaccines” Submission to Commission on Intellectual Property Rights, Innovation and Public Health, WHO.

See here for evidence that we were largely right: “We found no evidence that the AMC incentivizes innovation and increases availability… To sum up, the Brazilian stakeholder explicitly expresses the implicit criticism in the statements of the other interviewees, namely that the design of the AMC is poorly suited to the funding requirements, R&D agendas and marketing strategies of developing country vaccine manufacturers.” I repeatedly argued for focus on building capacity in LMICs, and that some of these initiatives were a distraction from building capacity in LMICs. The message only really hit home after the pandemic exposed the weaknesses.

An Analysis of the Problems of R&D Finance for Vaccines  April 2004. Reposted March 2005.  A PowerPoint presentation based on this paper for meetings in Malaysia (Neglected Diseases Group (NDG) Meeting, Universiti Sains Malaysia), Washington, London, and Austria is available on request

The Lancet The Lancet 364, 2011-2012. ” (Lancet pdf version) (plain pdf version) 4 December 2004 book review of “Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases” by Kremer, M. and Glennerster, R., Princeton University Press.